Levothyroxine: A black swan? [BE/BA News]

posted by DavidManteigas – Portugal, 2017-11-27 17:53 (1719 d 16:41 ago) – Posting: # 18014
Views: 7,192

There isn't any biological background that might explain this issue? Or problems during manufacturing? This is really awkward... the CI and point estimate are far more "perfect" than I am used to see. In fact, in full replicate studies, I've seen reference drugs "performing" poorly when compared with single administrations of themselves... Is the dose-toxicity so sensible for this drug that event the narrower limits does not apply in this case? Did a quick search and haven't find any study reporting the dose-response of this drug

Complete thread:

UA Flag
Activity
 Admin contact
22,301 posts in 4,667 threads, 1,585 registered users;
online 6 (0 registered, 6 guests [including 3 identified bots]).
Forum time: Saturday 11:34 CEST (Europe/Vienna)

In the field of observation,
chance favors only the mind that is prepared.    Louis Pasteur

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5